Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study by McConnachie, A. et al.
  
 
 
McConnachie, A., Walker, A., Robertson, M., Marchbank, L., Peacock, J., 
Packard, C.J., Cobbe, S.M., and Ford, I. (2014) Long-term impact on 
healthcare resource utilization of statin treatment, and its cost effectiveness 
in the primary prevention of cardiovascular disease: a record linkage study. 
European Heart Journal, 35 (5). pp. 290-298. ISSN 0195-668X 
 
 
Copyright © 2013 The Authors 
 
 
 
http://eprints.gla.ac.uk/83520 
 
 
 
Deposited on:  04 March 2014 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
CLINICAL RESEARCH
Prevention and epidemiology
Long-term impact on healthcare resource
utilization of statin treatment, and its cost
effectiveness in the primary prevention of
cardiovascular disease: a record linkage study
Alex McConnachie1, AndrewWalker1, Michele Robertson1, Laura Marchbank2,
Julie Peacock3, Christopher J. Packard4, Stuart M. Cobbe5, and Ian Ford1*
1Robertson Centre for Biostatistics, University of Glasgow, Glasgow G12 8QQ, UK; 2Information Services Division (ISD), NHS National Services Scotland, Paisley PA3 2SJ, UK;
3Information Services Division (ISD), NHS National Services Scotland, Edinburgh EH12 9EB, UK; 4Tennent Building, Western Infirmary, Glasgow G11 6NT, UK; and
5Department of Medical Cardiology, Glasgow Royal Infirmary, Glasgow G4 0SF, UK
Received 7 December 2012; revised 16 May 2013; accepted 30 May 2013; online publish-ahead-of-print 9 July 2013
Aims To assess the impact on healthcare resource utilization, costs, and quality of life over 15 years from 5 years of statin use in
men without a history of myocardial infarction in the West of Scotland Coronary Prevention Study (WOSCOPS).
Methods Six thousand fivehundred and ninety-fiveparticipants aged 45–54 yearswere randomized to 5 years treatmentwith pra-
vastatin (40 mg) or placebo. Linkage to routinely collected health records extended follow-up for secondary healthcare
resource utilization to 15 years. The following new results are reported: cause-specific first and recurrent cardiovascular
hospital admissions including myocardial infarction, heart failure, stroke, coronary revascularization and angiography;
non-cardiovascular hospitalization; days in hospital; quality-adjusted life years (QALYs); costs of pravastatin treatment,
treatment safety monitoring, and hospital admissions.
Results Five years treatment of 1000 patients with pravastatin (40 mg/day) saved the NHS £710 000 (P, 0.001), including the
cost of pravastatin and lipid and safety monitoring, and gained 136QALYs (P ¼ 0.017) over the 15-year period. Benefits
per 1000 subjects, attributable topreventionof cardiovascularevents, included163 feweradmissions and a savingof 1836
days in hospital, with fewer admissions for myocardial infarction, stroke, heart failure and coronary revascularization.
There was no excess in non-cardiovascular admissions or costs (or in admissions associated with diabetes or its compli-
cations) and no evidence of heterogeneity of effect over sub-groups defined by baseline cardiovascular risk.
Conclusion Five years’ primary prevention treatment of middle-agedmenwith a statin significantly reduces healthcare resource util-
ization, is cost saving, and increasesQALYs. Treatment of even younger, lower risk individuals is likely to be cost-effective.
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Introduction
TheWestof ScotlandCoronary Prevention Study (WOSCOPS)was
a randomized placebo-controlled primary prevention trial of pravas-
tatin inmiddle-agedmen.1–3 Five years of treatment with pravastatin
reduced the primary outcome of death from coronary heart disease
(CHD)ornonfatalmyocardial infarction (7.9%onplacebo to5.5%on
pravastatin, P, 0.001). Definite or suspected CHD deaths were
also reduced (1.9–1.3%, P ¼ 0.04) with no increased risk of death
from non-cardiovascular causes nor an increase in incident
cancers.3 Post-trial extended follow-up for a further 10yearsdemon-
strated a continued reduction in coronary events with no emerging
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safety issues.Overall, over 15 years, therewas a reduction in all-cause
mortality [hazard ratio, HR ¼ 0.88, 95% CI (0.79–0.99), P ¼ 0.03]
and in coronary heart disease death or hospitalization [HR ¼ 0.75,
95% CI (0.68–0.83), P, 0.001].4
A previous cost-effectiveness analysis modelled post-trial benefits
only on the basis of deaths prevented due to the reduction of coron-
ary events within the formal 5-year trial.5
Recently, the cost effectiveness of statin treatment in a primary
prevention context has been questioned,6 as was the use of statins
in healthy men.7 In this extended analysis of the WOSCOPS long-
term follow-up, we directly address these issues and incorporate
new data on cardiovascular cause-specific reasons for admission to
hospital (first and recurrent), non-cardiovascular admissions (includ-
ing diabetes-related admissions), duration of admission, use of angi-
ography and coronary revascularization, leading to an assessment
of the costs and effectiveness of statin treatment in the primary pre-
vention of cardiovascular disease.
Methods
Original trial
The design of WOSCOPS and its follow-up have been described else-
where.1–4 It was a randomized trial comparing pravastatin (40 mg once
daily) with placebo in men, aged 45–64 years, with hypercholesterol-
aemia who had no evidence of previous myocardial infarction. The trial
was approved by the ethics committees of the University of Glasgow
and participating health boards in Scotland. Between 1989 and 1991,
6595 men gave written informed consent and were randomized. The
average follow-up was 4.9 years with final study visits in May 1995.
Post-trial follow-up
The post-trial use of lipid-lowering therapy was similar (38.7 and 35.2%
in the pravastatin and placebo arms, respectively) in the two groups
during the first 5 years of extended follow-up.4 All follow-up in this
report, both within-trial and post-trial, is from electronic linkage to hos-
pital discharge records, the cancer registry and General Register Office
death records using established methods, and includes both first and re-
current events.8,9
Outcome determination
Outcomes were identified using the International Classification of Dis-
eases codes and Office of Population, Censuses and Surveys Classifica-
tion of Surgical Operations and Procedures codes until December
2004. Follow-up and record linkage was approved by the ethics commit-
tee of the Royal Infirmary, Glasgowand the Privacy Advisory Committee
of the National Health Service for Scotland.
Previous analyses4 focussed on time-to-first event for deaths, incident
cancers, and composite cardiovascular outcomes. Here, we have analysed
in detail healthcare resource utilization (cause-specific hospital admissions,
length of stay and need for coronary investigations, procedures and opera-
tions),with theconsequent impactonthequalityof life, additionalhealthcare
costs resulting from a change in disease status after a hospital admission (re-
ferred to herein as ‘incremental costs of events’) and cost effectiveness.We
focussed on cardiovascular admissions involving myocardial infarction,
stroke, coronary artery bypass grafting (CABG), percutaneous coronary
intervention (PCI), coronary angiography, any coronary cause (including
CABG, PCI, or coronary angiography), and heart failure. Myocardial infarc-
tion and stroke events were considered outcomes whether or not they
were the reason for admission. Other coronary or heart failure codes had
to be the primary discharge diagnosis to be counted. Each admission
could be represented more than once across the various outcomes. For
the length of stay and cost of the acute admissions, each continuous
periodof in-patient staywas categorizedunder themost significant included
event, definedhierarchicallyas a stroke if theperiodof stay involveda stroke,
otherwise as a myocardial infarction, otherwise as heart failure, and other-
wise as a coronary event if it involved another coronary reason. The com-
posite of these hospitalizations is described as cardiovascular. Other
hospitalizations are classed as non-cardiovascular. Because of recent con-
cerns about increased incidence of diabetes in statin-treated individuals,
we specifically identified hospitalizations where diabetes or its complica-
tions was given as the reason for admission or as a complicating factor.
Because of the reduction in cardiovascular hospital admissions associated
with statin use, we analysed diabetes-related admissions overall and within
hospital admissions with non-cardiovascular causes.
Statistical methods
Cumulative incidence functions, accounting for the competing risk of
death from other causes, were used to describe the incidence of
events. Cause-specific Cox proportional hazards models were fitted
including the treatment group and baseline risk factors as described pre-
viously4 [age, body mass index, systolic and diastolic blood pressures,
high- and low-density lipoprotein cholesterol levels, log-transformed tri-
glyceride level, nitrate use, historyof angina, historyof diabetes, historyof
hypertension (all yes or no), smoking status (current, former, never), and
a social deprivation score].10 Effectsof randomized treatment assignment
(pravastatin versus placebo) were expressed as HRs with 95% confi-
dence intervals and corresponding P values. Although it was plausible
that the proportional-hazards assumption would not be valid over the
full period of follow-up, we concluded that the estimated HRs would
still reflect an average effect over the period.
For the hierarchical groupings of continuous periods of hospital stay,
total days of admission and lengths of stay for those admitted to hospital
were compared between treatment groups using re-randomization
t-tests. Re-randomization t-tests were used as a precaution because of
the highly non-Normal distribution of these data, particularly the large
numbers of zero values.
Economic evaluation
We evaluated the costs and benefits of the initial 5 years treatment with
pravastatin over the full available follow-up period of 15 years in a
cost-utility analysis, as this allows a comparison with other uses of
health care resources. We used the perspective of the NHS for costs
and savings, and health benefits [measured in quality-adjusted life years
(QALYs) over the follow-up period of 15 years] for patients; this is con-
sistent with health technology assessments carried out by NICE.
NHS Scotland staff, blinded to randomized treatment, assignedHealth
Resource Grouping codes to each acute hospital episode, to enable
costing with NHS Scotland Tariff costs.11 We used current (2012)
costs of £9.0712 for a 3-month prescription for 40 mg pravastatin and cal-
culated drug costs from the months of pravastatin used in the trial. In the
post-trial period, the 3% excess of statin treatment in the pravastatin
group was extrapolated throughout the follow-up. We assumed two
liver function and cholesterol tests at the initial consultation, repeated an-
nuallywhilston statin treatment (£1.34/test, plus £31 for the initial doctor
consultation and £10/annum for nurse consultations).
Table 1 shows the incremental costs of events for care after discharge
fromhospital andwas basedon a previousHealth TechnologyAssessment
(HTA)report13 andupdated to2011costsusing theHospital andCommu-
nity Health Services Index.14 The incremental costs of events reflect out-
patient follow-up, primary and community services and reduce after the
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first year. Formultiple events, only the highest applicable additional health-
care costs was used.
Quality of life was assumed to decline with age according to equation:
1.060–0.004 × age (in years).Quality of lifewas decremented after each
admission using the factors given in Table 1 and was set to zero at death.
The disutilities shown in Table 1 were taken from the previous HTA
report.13 quality-adjusted life years were calculated over the 15-year
horizon of the study.
Cumulative mean costs and QALYs per 1000 patients randomized
were calculated for each treatment group and compared using boot-
strapping with 5000 replicates to calculate P values and 95% confidence
intervals. Analyses were repeated after discounting costs and
quality-of-life decrements at a rate of 3.5% per annum, reflecting the
rate recommended by the UK government.
Wecreated threeapproximately equal sub-groupson thebasisof their
estimated cardiovascular risk using theASSIGNRisk score.15 Participants
with a history of angina or stroke or a positive rose questionnaire for
angina were assigned to the highest-risk group.
Results
Time-to-first event analyses
Time-to-event analyses arepresented inTable 2 and Figure1. Reflecting
within-trial results for fatal and non-fatal cardiovascular outcomes,
myocardial infarction risk was reduced by 31% (P, 0.001), CHD ad-
mission risk by 26% (P, 0.001), and stroke risk by 19% (P ¼ 0.038).
There were 31, 27, and 31% reductions in the need for PCI, CABG,
and use of angiography (P ¼ 0.009, 0.003, and ,0.001, respectively).
There was a 43% reduction in the risk of admission for heart failure
(P ¼ 0.002) and a 28% reduction in overall cardiovascular admissions
(P, 0.001). There was no evidence of a difference in the risk of non-
cardiovascular admissions [HR 0.99, 95% CI (0.94, 1.05), P ¼ 0.75)].
Overall hospital admissions associated with diabetes occurred in 142
participants randomized toplaceboand128randomized topravastatin
[HR 0.78, 95% CI (0.60, 1.00), P ¼ 0.05]. When restricted to hospital
admissions classed as non-cardiovascular, these occurred in 105 and
102 participants in the placebo and pravastatin groups, respectively,
P ¼ 0.29. Figure 1A–D shows the cumulative incidence functions for
PCI or CABG, all CHD, heart failure, and stroke admissions. For PCI
or CABG and CHD admissions, there is evidence of benefit during
the initial trial period with a strong suggestion of ongoing benefit. For
stroke, and particularly for heart failure, most of the benefit appears
to accumulate in the post-trial period.
Days in hospital, mean length of stay
During 15 years of follow-up, patients allocated originally to the
placebo arm spent 20 447 days in hospital for cardiovascular
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table2 Numbersof subjectswithat leastoneeventand totalnumbersofeventsoccurringoveraperiodof approximately
15 years for hospital admissions involving the various types of event (events are not necessarilymutually exclusive), split by
randomized treatment group
Event type Placebo (n5 3293) Pravastatin (n5 3302) HR P value
Subjects Events Subjects Events HR (95% CI)
MI 369 426 265 311 0.69 (0.59, 0.81) ,0.0001
PCI 119 137 84 90 0.69 (0.52, 0.91) 0.0089
CABG 209 213 157 159 0.73 (0.59, 0.90) 0.0031
Angiography 356 417 255 304 0.69 (0.59, 0.81) ,0.0001
CHD 755 1707 586 1264 0.74 (0.66, 0.82) ,0.0001
HF 80 130 48 69 0.57 (0.39, 0.81) 0.0018
Stroke 216 341 184 305 0.81 (0.67, 0.99) 0.038
Any CV 935 2131 727 1598 0.72 (0.66, 0.80) ,0.0001
Non CV 2476 11362 2496 11680 0.99 (0.94, 1.05) 0.75
Hazard ratios (HR) (pravastatin vs. placebo), 95% confidence intervals and P values are derived from Cox proportional hazards models for time-to-first event analyses.
MI, myocardial infarction; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; CHD, coronary heart disease; HF, heart failure; CV, cardiovascular.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Incremental costs of events and quality of life decrements applied following each type of cardiovascular event
Event Type Additional healthcare costs
First year after discharge Second and subsequent
years after discharge
Quality-of-life decrement
as percentage of baseline
1: Stroke £9248 £2486 237.1%
2: MI £506 £197 224%
3: HF £506 £197 223%
4: Other CHD £197 £197 219%
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conditions compared to 14 440 for those allocated to pravastatin
(P ¼ 0.003) (Table 3). Therewere trends to reductions for all cardio-
vascular admission subtypes with statistically significant reductions
for myocardial infarction and other coronary admissions. Average
lengths of stay did not differ between treatment groups, nor did
the total length of stay for non-cardiovascular causes.
Acute admission, incremental costs
of events, and drug and monitoring costs
In Table 4, we present the costs of acute admissions, treatment and
monitoring, and the incremental costsof eventswith andwithout dis-
counting at 3.5% per annum.
Figure1 Cumulative incidence curves for cause specific admission tohospital [(A) forCABGorPCI, (B) forCHD, (C) forHeart Failure and (D) for
Stroke], split by a randomized treatment group.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3 The table contains the number of subjects, number of events, total length of continuous periods of hospital stay
(LOS) and mean length of continuous periods of hospital stay
Event type Placebo (n5 3293) Pravastatin (n 5 3302) PT PM
Subjects Events Total LOS
(days)
Mean LOS
(days)
Subjects Events Total LOS
(days)
Mean LOS
(days)
Any CV 935 2131 20447 10.68 727 1598 14440 10.34 0.0026 0.80
Stroke 216 341 9296 26.94 184 305 6754 25.02 0.27 0.78
MI 362 416 3523 8.47 260 301 2484 8.29 ,0.0001 0.73
HF 76 122 1713 14.71 47 67 828 10.26 0.074 0.17
Other
CHD
536 1252 5915 4.75 433 925 4374 4.71 0.0022 0.91
Non CV 2476 11362 48248 4.17 2496 11680 49298 4.19 0.70 0.90
All cardiovascular event type categories aremutually exclusivewith periods of stay classified hierarchically as stroke if the period involved a stroke, otherwise asmyocardial infarction
(MI) if it involved myocardial infarction, otherwise as heart failure (HF) if it involved HF and otherwise as other coronary heart disease (CHD) if it involved another coronary heart
disease event. The table also contains P values comparing the total length of continuous inpatient stay (PT) and mean length of continuous periods of inpatient stay (PM, comparing
subjects in each group with at least one hospital admission)) between the randomized treatment groups.
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Net costs and quality-adjusted life years
Net costs and QALYs are reported in Table 5. There was no impact
onnon-cardiovascular admission costs.Weestimated that treatment
of 1000 patients for an initial 5 years with pravastatin (40 mg/day)
would save the NHS £710 000 (P, 0.001) and generate a gain of
136 QALYs (P ¼ 0.017), over 15 years of follow-up.
In the three subgroups defined according toASSIGNbaseline risk,
actual 10-year placebo-group risks were estimated for the two out-
comes defined by (i) coronary death or non-fatal myocardial infarc-
tion (MI) and (ii) coronary or stroke death, MI or stroke
hospitalization, or PCI or CABG. The 10-year risks for the (low-,
medium-, high-) risk groups were (7.5, 10.1, 17.8%) and (10.3, 17.1,
28.0%) for these two outcomes, respectively. Our analyses by sub-
groups of baseline risk did not reveal any evidence of heterogeneity
in the cost savings or QALYs gained (Table 6).
Figure 2 shows the development of the cardiovascular cost savings
and QALY gains over time suggesting ongoing accumulation of ben-
efits at 15 years. In Figure 3, we show results of 5000 bootstrap simu-
lations presented in the cost-effectiveness plane defined by themean
cost difference and the mean QALY difference.
Sensitivity analyses
Sensitivity analyses (Appendix) suggests that our conclusions are
robust to reasonable changes in key parameters. A 25% reduction
in admission costs changed the cardiovascular savings per 1000
patients over 15 years from £710 100 in the base case to £555 000.
A reduction in the assumed health loss from a cardiovascular event
by 25% changed the QALY gain per 1000 patients over 15 years
from 136 to 120. The only scenario without net cost savings was
where we multiplied the prescribing and monitoring costs by
5. Here, the added cost per 1000 patients was £112 000, and the
added cost per QALY gained (£112 000/136) was £824.
Discussion
Cardiovascular effects
We have significantly extended the results reported previously that
show that 5 years of treatmentwith a statin, inmiddle-aged hyperch-
olesterolaemicmenwithout a history of myocardial infarction, leads
to long-term benefit by reducing coronary and all-cause death and
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 4 Distribution of participants by numbers of cardiovascular (CV) hospital admissions occurring in long-term
follow-up
Number of CV hospital admissions
0 1 2 3 4 5 6 7 >7
Placebo 2358 453 227 95 70 36 21 11 22
Pravastatin 2575 344 184 83 51 34 11 6 14
P, 0.001, chi-square test.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 5 Total assumed average cost (in £) of hospital care based on HRGs
Undiscounted costs Discounted costs
Placebo (N 5 3293) Pravastatin (N 5 3302) Placebo (N 5 3293) Pravastatin (N 5 3302)
Acute costs
Any cardiovascular 10 409 011 7 888 709 7 807 932 5 918 407
Stroke 2 275 133 1 868 289 1 642 418 1 335 683
MI 2 098 593 1 540 131 1 647 004 1 196 578
HF 646 103 413 505 457 378 297 868
Other CHD 5 389 182 4 066 784 4 061 133 3 088 278
Cardiovascular admission additional
healthcare costs
4 626 854 3 357 666 3 296 839 2 397 851
Treatment and monitoring costs – 724 074 – 706 647
Acute costs
Non-cardiovascular 25 275 491 25 329 616 18 998 233 19 036 472
All cardiovascular event type categories aremutually exclusivewith periods of stay classified hierarchically as stroke if the period involved a stroke, otherwise asmyocardial infarction
(MI) if it involved myocardial infarction, otherwise as heart failure (HF) if it involved HF and otherwise as other coronary heart disease (CHD) if it involved another coronary heart
diseaseevent.Also shownareestimatedpost admission incremental costsof events for cardiovascular admissions, andpravastatin treatment andassociated lipid and safetymonitoring
costs within the pravastatin group. Costs are shown without and with discounting at an annual rate of 3.5%.
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coronary events. The current analysis of health care resource utiliza-
tion indicated that these benefits were accompanied by a reduction
in the risk of a first hospital admission for a cardiovascular event (myo-
cardial infarction, stroke, heart failure, and hospitalizations involving
PCI, CABG, or angiography or any other coronary cause). Recurrent
cardiovascular events of all such typeswere reducedwith substantially
fewer days spent in hospital. To put this in perspective, we estimate
that treatment of 1000 WOSCOPS-eligible patients for 5 years
would prevent 163 cardiovascular inpatient stays (involving 1836
days in hospital), including 35 myocardial infarctions, 11 strokes, 17
heart failure admissions, and 100 involving other aspects of coronary
heart disease (including 14 PCIs, 17 CABGs, and 35 coronary angio-
grams), over a period of 15 years. The resulting acute cardiovascular
hospitalization savings (per 1000 treated with pravastatin) to the
NHS are estimated to be £771 881 with additional healthcare costs
savings of £388 199, all at a cost of £219 283 for pravastatin treatment
(at 2012 prices) and monitoring costs (undiscounted figures), giving
the net undiscounted savings of £941 397.
Figure 2 Figures showing the cumulative cardiovascular cost differences (A) and mean quality-adjusted life year differences (B) for pravastatin
group - placebo group over time, with 95% confidence intervals. Estimates are shown as solid lines and 95% confidence bounds as dotted lines.
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Table 6 Cumulative mean costs (per 1000 people treated) and quality-adjusted life years after 15 years, in those originally
randomized to receive pravastatin or placebo, withmean, 95% confidence interval, and P value for the difference between
randomized groups (pravastatin2 placebo)
Placebo Pravastatin Difference (Prava 2 Plac) Interaction P value
Cardiovascular disease costs (£million/1000 people)
All 3.55 2.84 20.71 (21.09 to 20.32), P, 0.001
Low risk 2.11 1.27 20.84 (21.27 to 20.42), P, 0.001 0.85
Intermediate risk 3.47 2.89 20.58 (21.27 to 0.08), P ¼ 0.086
High risk 5.04 4.36 20.68 (21.49 to 0.11), P ¼ 0.088
QALYs (per 1000 people)
All 11 057 11 193 136 (25 to 247), P ¼ 0.017
Low risk 11 905 12 016 111 (212 to 238), P ¼ 0.079 0.95
Intermediate risk 11 075 11 207 131 (251 to 309), P ¼ 0.17
High risk 10 220 10 371 151 (272 to 376), P ¼ 0.18
Non-Cardiovascular disease costs (£million/1000 people))
All 6.00 6.03 0.03 (20.44 to 0.52), P ¼ 0.87
Low risk 4.42 4.33 20.09 (20.81 to 0.66), P ¼ 0.83 0.65
Intermediate risk 5.84 6.20 0.36 (20.44 to 1.18), P ¼ 0.37
High risk 7.68 7.55 20.13 (21.00 to 0.75), P ¼ 0.78
Costs shownare for all cardiovascular admissions and incremental costs of events, plus treatment andmonitoring costs, and for non-cardiovascular disease admission costs.Costs and
quality-adjusted life years shown for all randomized subjects, and separately by thirds of cardiovascular risk. Interaction P values testwhether between-treatment differences are equal
across cardiovascular risk groups. All costs and quality-adjusted life year decrements are discounted annually at 3.5%. Costs are given in units of £1 million.
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Non-cardiovascular effects
We found no evidence of any increase in hospitalization for non-
cardiovascular causes, or in the associated costs. In particular, we
foundnoevidenceof anyexcess in-hospital admissions related todia-
betes or its complications.
Interpretation
Reducing days spent in a hospital for cardiovascular causes and pre-
venting the need for coronary revascularization procedures and
surgery have significant benefits for the health service and patients.
After discounting, there was a net saving to the NHS over 15 years
with an associated gain of QALYs. Analysis of subgroups according
to the baseline risk did not identify heterogeneity of these effects
across subgroups. The suggestion of longer-termbenefits in prevent-
ing strokes and heart failure admissions is interesting, possibly as a
consequence of preventing earlier coronary events and slowing
disease progression and hints at the potential for even greater cost
savings and better quality of life in the pravastatin-allocated group
with longer follow-up.
Results in a broader context
Interest in the cost-effectiveness of statin treatment, particularly in
the primary prevention context, shows no signs of waning. Our ana-
lysis adds to existing knowledge in two ways.
First, previous analyses have focussed on model-based extrapola-
tions from trial results, and none had access to actual long-term
follow-up data. In WOSCOPS, we had the opportunity to link elec-
tronically to comprehensive national databases of hospital discharges
and deaths, providing information on estimated costs and benefits
overameaningful periodof time, andwewereable toderiveevidence
of cost savings and patient benefits without extrapolating results into
veryold ageswhere the complexities ofmulti-morbiditymake typical
unvalidated modelling assumptions open to question. Second, our
analyses suggest that statins are even more cost-effective in
primary prevention than had previously been suspected. While
most economic evaluations have concluded that the cost per
QALY is within acceptable limits, previous evaluations have not sug-
gested that statin prescribing in this patient group could be cost
saving. This, in combination with our risk-based sub-group analyses,
raises the prospect that statin treatment could be cost saving at
lower levels of risk than was previously suspected.
For example, a previousWOSCOPS economic evaluation,5 based
on amodel that extrapolated lifetime benefits only via the prevention
of within-trial coronary events, estimated an added cost per life-year
gainof £20 375 (1996prices),which is amuch less favourable estimate
than that indicated inourcurrent analysis.More recently, an economic
evaluation ina low-riskpopulation,16wasbasedona reviewof trial and
Canadian registry data. In a ‘low-potency statin’ versus ‘no statin’ com-
parison, the authors predicted an added cost per QALY of
Can$30 000 (about £20 000) using a lifetime perspective; low risk
wasdefinedas a10-year riskof≤20% forcardiovasculardeathornon-
fatalMI. For this typeofendpoint, theWOSCOPS10-yearplaceborisk
is12.8%overall and7.7, 10.8, and20.0% inour low-,medium-andhigh-
risk subgroups defined by baseline ASSIGN risk. Their QALY esti-
mates were similar to ours. The difference between our results and
those of the Canadian registry study is in the hospital admissions
and consequent savings from reducing these over time: the actual
rates in our data are much more favourable to statin treatment.
Our results are based on the treatment with pravastatin 40 mg, a
drug that is well tolerated but is recognized as being less potent
than widely used agents such as atorvastatin and rosuvastatin. It
is likely that more potent statins, particularly at higher doses,
would confer greater benefits in reducing the cardiovascular risk.
However, there are safety issues associated with using more
potent statins at the highest doses, and higher doses of statins have
been linked recently with an increased risk of new-onset diabetes.17
In the context of treating younger, lower risk individuals with a
statin for a lifetime, the drive to improve a patient’s cardiovascular
risk profile would have to be balanced against issues of tolerability
and safety. In WOSCOPS we have reported previously a lower
rate of new-onset diabetes in the participants randomized to pravas-
tatin over the 5 years of randomized treatment.18 The meta-analysis
of incident diabetes risk in statin trials,17 although suggesting a
modest overall increase in the risk of diabetes with statin treatment,
also suggested an interaction with participant age, with oldest parti-
cipants having the greatest increase in the risk of diabetes on statin
treatment. WOSCOPS participants had the lowest mean age in the
meta-analysis. In combination with the fact that we found no sug-
gestion of an increase in diabetes-associated hospital admissions
over 15 years of follow-up, we believe that this evidence provides
reassurance about the long-term safety of treating middle-aged
subjects for 5 years with pravastatin at a dose of 40 mg.
Limitations of our analysis
While there are undoubted strengths in our approach, there are also
limitations. Our follow-up spans a period during which the manage-
ment of cardiovascular events (e.g. the increase in use of coronary
revascularization) and even event definitions (myocardial infarction)
Figure 3 Plot of bootstrap results on the cost-effectiveness
plane.
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changed.Wehaveavoided the issueof trends inhospital lengthof stay
by using a cost per event reflecting current practice in many coun-
tries. Record linkage is subject to error, and there is a possibility
that some events have been missed and some wrongly assigned and
that coding variation may have mis-assigned reasons for admission.
However, we believe that these issues are minor and if anything
would add noise and serve only to reduce any treatment effects
detected. In any case, these factors will apply equally to both treat-
ment arms. WOSCOPS patients have not all been followed up to
death and hence we cannot, without extrapolation, project to life-
time benefits. Nevertheless, it is all the more remarkable that we
were able to demonstrate cost savings over a finite time period. In
fact, this could be seen as an advantage as we avoid the need for ex-
trapolating benefits to the complex situation at the end of life in the
very old. While the events, hospital admissions, and deaths are
observed, we had to estimate costs and quality-of-life impacts retro-
spectively. For acute costs, we selected national tariff rates and for
utilities and incremental costs of events from a previously published
independent health technology assessment report. We also sub-
jected these assumptions to sensitivity analysis and have shown
that if the figures are changed by 25% in a direction that reduces
the cost-effectiveness of statin prescribing then our conclusions
would be unchanged. Although an increase in the costs of pravastatin
treatment and monitoring by a factor of 5 removed the cost savings
in our analysis, this scenario is particularly unlikely given the fact
that monitoring of patients is much less common in practice than
we have assumed in the model and likely to become even less so
because of recent FDA advice not to carry out long-term routine
liver function monitoring. Our sub-group analysis by baseline risk is
possibly underpowered. Nevertheless, if anything, there was a trend
to greater cardiovascular cost savings in the lowest risk subjects.
Finally, our findings are limited to randomized allocation to placebo
or pravastatin over 5 years. It seems inevitable that longer treatment
with a statin, for instance lifetime treatment, which would be normal
clinical practice, would yield greater cardiovascular health gains.
However, we cannot say with certainty that this would be more cost-
effective. In addition, although in this population of middle-aged men
treatedwith pravastatin 40 mg/day,we foundno evidenceof increased
risk of diabetes within the trial or of risk of hospital admission asso-
ciated with diabetes or its complications in the 15 years of follow-up,
we cannot extrapolate these safety findings to patients treated for
much longer periods.
Conclusions
Five years of treatment with pravastatin 40 mg of middle-aged men
with hypercholesterolaemia and no history of myocardial infarction
significantly reduced cardiovascular hospital admissions, incremental
costs of events and net costs taking into account the cost of the drug
and associated monitoring. Quality adjusted life years lived were sig-
nificantly increased. There was no evidence of any increase in non-
cardiovascular admissions or associated costs. These effects, seen
across a range of underlying cardiovascular risks, suggest that treat-
ment of even lower-risk individuals would still be economically effi-
cient and deliver significant public health benefits. Our results add
to and support a recent call for expanded use of statins.19 However,
there remains uncertainty in relation to the potential for increased
risk of diabetes with treatment of more than 5 years duration.
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Appendix
Sensitivity analyses. Estimated difference (pravastatin—placebo, with
95% CI) between those originally randomized to receive pravastatin
or placebo for the cumulative mean costs (per 1000 people treated)
and QALYs after 15 years, under alternative scenarios. Costs include
all cardiovascular hospitalizations and associated additional healthcare
costs,pluspravastatin treatmentandmonitoringcosts.Alternativescen-
arios are: hospitalization costs +25%; additional healthcare costs
+25%; 50% reduction; and two- and five-fold increase in treatment/
monitoring costs; QALY decrements +25%. All costs and QALY
decrementsarediscountedat3.5%.Costsaregiven inunitsof£1million.
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Costs (£) (per 1000 people) QALYs
Base case 20.71 (21.09 to 20.32) 136 (25–247)
Changes to hospitalization costs
+25% 20.86 (21.30 to 20.41)
225% 20.56 (20.88 to 20.22)
Changes to incremental costs of events
+25% 20.78 (21.20 to 20.36)
225% 20.64 (20.98 to 20.28)
Changes to treatment and monitoring costs
/2 20.81 (21.19 to 20.42)
×2 20.50 (20.89 to 20.16)
×5 0.11 (20.27 to 0.50)
Changes to QALY decrements
+25% 153 (40–265)
225% 120 (10–230)
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